Mirae Asset Global Investments Co. Ltd. Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Mirae Asset Global Investments Co. Ltd. bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 52,099 shares of the medical equipment provider’s stock, valued at approximately $4,628,000.

A number of other large investors have also modified their holdings of ZBH. OMERS ADMINISTRATION Corp acquired a new position in Zimmer Biomet during the 2nd quarter worth $922,000. Hsbc Holdings PLC purchased a new stake in shares of Zimmer Biomet during the second quarter worth approximately $35,417,000. Nykredit A S acquired a new stake in shares of Zimmer Biomet in the 2nd quarter valued at $3,419,000. Legal & General Group Plc acquired a new stake in Zimmer Biomet in the second quarter valued at $126,167,000. Finally, Rakuten Investment Management Inc. purchased a new stake in Zimmer Biomet during the second quarter worth approximately $2,945,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 2.8%

Shares of ZBH opened at $107.08 on Friday. The company has a market capitalization of $20.42 billion, a PE ratio of 12.99, a price-to-earnings-growth ratio of 2.65 and a beta of 0.50. The stock has a fifty day moving average of $95.01 and a two-hundred day moving average of $91.99. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $112.54. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.94 and a current ratio of 1.46.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The firm had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. During the same period last year, the company earned $1.90 EPS. The firm’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a $0.24 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Transactions at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is currently owned by insiders.

Key Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Zimmer Biomet’s third-quarter sales of $2.063 billion and adjusted EPS of $1.90 topped analyst estimates. The company also raised its full-year 2026 outlook; hip and S.E.T. sales helped offset softer knee results. Third-quarter results
• Positive Sentiment: Analysts raised targets, with UBS moving to $130 and keeping a Buy rating, and RBC increasing its target to $125 with an Outperform rating. These revisions signal improved expectations for the shares. UBS analyst rating
• Neutral Sentiment: JPMorgan, Citi, and Wells Fargo also lifted their price targets, but retained Neutral or Equal Weight ratings. Bernstein raised its target to $107 while maintaining Market Perform, reflecting a more cautious view.
• Negative Sentiment: Knee-market challenges and margin pressure temper the results. Reported diluted EPS fell 13.8% year over year to $1.00, although adjusted EPS was flat at $1.90, so investors may weigh the outlook improvement against operating pressures. Quarterly outlook and knee-market challenges

Analyst Ratings Changes

ZBH has been the subject of several research analyst reports. Sanford C. Bernstein upped their price objective on shares of Zimmer Biomet from $93.00 to $107.00 and gave the company a “market perform” rating in a research note on Thursday. Weiss Ratings raised shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Wells Fargo & Company boosted their target price on Zimmer Biomet from $103.00 to $113.00 and gave the stock an “equal weight” rating in a research report on Thursday. Argus reiterated a “buy” rating and issued a $125.00 price objective on shares of Zimmer Biomet in a research note on Thursday, October 22nd. Finally, UBS Group boosted their target price on Zimmer Biomet from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday. Seven equities research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $111.95.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.